title: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
abstract: Multiple systems have been developed for grading the adverse effects (AEs) of cancer treatment. The National Cancer Institute Common Toxicity Criteria (CTC) system has substantially evolved since its inception in 1983. The most recent version, CTCAE v3.0 (Common Terminology Criteria for Adverse Events version 3.0) represents the first comprehensive, multimodality grading system for reporting the acute and late effects of cancer treatment. The new CTC requires changes in the application of AE criteria including new guidelines regarding late effects, surgical and pediatric effects, multimodality issues, and for reporting the duration of an effect. It builds on the strengths of previous systems, represents a considerable effort among hundreds of participants, and signifies an international collaboration and consensus of the oncology research community. This article updates recent progress in the evolution of adverse effects grading systems and reviews the development of CTCAE v3.0.
authors.affiliation: H. Lee Moffitt Cancer Center at the University of South Florida, Tampa, FL 33612, USA. Trotti@moffitt.usf.edu
authors.forename: Andy
authors.initials: A
authors.lastname: Trotti
authors.forename: A Dimitrios
authors.initials: AD
authors.lastname: Colevas
authors.forename: Ann
authors.initials: A
authors.lastname: Setser
authors.forename: Valerie
authors.initials: V
authors.lastname: Rusch
authors.forename: David
authors.initials: D
authors.lastname: Jaques
authors.forename: Volker
authors.initials: V
authors.lastname: Budach
authors.forename: Corey
authors.initials: C
authors.lastname: Langer
authors.forename: Barbara
authors.initials: B
authors.lastname: Murphy
authors.forename: Richard
authors.initials: R
authors.lastname: Cumberlin
authors.forename: C Norman
authors.initials: CN
authors.lastname: Coleman
authors.forename: Philip
authors.initials: P
authors.lastname: Rubin
mesh_terms: D000047:Academies and Institutes; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D007255:Information Services / Q000458:organization & administration*; D009369:Neoplasms / Q000628:therapy*; D011878:Radiotherapy / Q000009:adverse effects*; D013514:Surgical Procedures, Operative / Q000009:adverse effects*; D009626:Terminology as Topic
chemical_list: D000970:Antineoplastic Agents